| Protein Degradation and Inhibitors | Lifetime | 26 | DE 1 | 99.72 |
| Cancer Mechanisms and Therapy | Lifetime | 22 | DE 2 | 99.48 |
| Histone Deacetylase Inhibitors Research | Lifetime | 35 | DE 2 | 99.49 |
| Ubiquitin and proteasome pathways | Lifetime | 76 | DE 5 | 99.51 |
| Peptidase Inhibition and Analysis | Lifetime | 110 | DE 9 | 99.45 |
| Multiple Myeloma Research and Treatments | Lifetime | 155 | DE 8 | 98.96 |
| Enzyme Structure and Function | Lifetime | 358 | DE 48 | 98.53 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 233 | DE 14 | 98.24 |
| Melanoma and MAPK Pathways | Lifetime | 192 | DE 18 | 97.84 |
| Computational Drug Discovery Methods | Lifetime | 882 | DE 48 | 96.73 |
| Biochemical and Molecular Research | Lifetime | 544 | DE 32 | 96.74 |
| Cancer-related Molecular Pathways | Lifetime | 833 | DE 39 | 97.32 |
| Protein Tyrosine Phosphatases | Lifetime | 179 | DE 11 | 95.37 |
| Click Chemistry and Applications | Lifetime | 722 | DE 95 | 95.80 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 576 | DE 14 | 95.82 |
| 14-3-3 protein interactions | Lifetime | 148 | DE 9 | 93.45 |
| Quinazolinone synthesis and applications | Lifetime | 614 | DE 22 | 91.62 |
| Chromatin Remodeling and Cancer | Lifetime | 410 | DE 44 | 90.99 |
| Ubiquitin and proteasome pathways | 2021-2025 | 12 | DE 3 | 98.76 |
| Protein Degradation and Inhibitors | 2021-2025 | 47 | DE 4 | 99.01 |
| Peptidase Inhibition and Analysis | 2021-2025 | 177 | DE 19 | 95.92 |
| Signaling Pathways in Disease | 2021-2025 | 38 | DE 4 | 89.18 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 38 | DE 4 | 89.28 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 289 | DE 20 | 88.43 |
| Cancer-related Molecular Pathways | 2021-2025 | 269 | DE 14 | 88.08 |
| Cancer therapeutics and mechanisms | 2021-2025 | 388 | DE 10 | 83.65 |
| Click Chemistry and Applications | 2021-2025 | 553 | DE 20 | 85.00 |
| Biochemical and Molecular Research | 2021-2025 | 254 | DE 14 | 80.94 |
| Protein Tyrosine Phosphatases | 2021-2025 | 133 | DE 8 | 78.05 |
| Microtubule and mitosis dynamics | 2021-2025 | 449 | DE 29 | 78.07 |
| Cancer Mechanisms and Therapy | 2021-2025 | 650 | DE 19 | 76.78 |
| Melanoma and MAPK Pathways | 2021-2025 | 571 | DE 60 | 76.84 |
| Quinazolinone synthesis and applications | 2021-2025 | 317 | DE 7 | 75.16 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 653 | DE 42 | 71.88 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 362 | DE 19 | 71.90 |
| Estrogen and related hormone effects | 2021-2025 | 977 | DE 31 | 70.09 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 586 | DE 29 | 60.99 |
| Nuclear Receptors and Signaling | 2021-2025 | 618 | DE 33 | 56.85 |
| Cell death mechanisms and regulation | 2021-2025 | 991 | DE 49 | 41.27 |
| Synthesis and Reactivity of Heterocycles | 2021-2025 | 443 | DE 13 | 36.18 |
| NF-κB Signaling Pathways | 2021-2025 | 897 | DE 62 | 29.05 |
